Structure of compound 60b

RSV D486N-mut. fusion protein inh.

oral antiviral clinical candidate

from lower barrier to atropisomerism of lead

Bioorg. Med. Chem., Oct. 31, 2020

Taisho Pharmaceutical, Saitama, JP

“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.